Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib
作者： H. Schmid , B. A.S. Jaeger , J. Lohse , M. Suttorp
DOI: 10.3324/HAEMATOL.2009.008359
关键词:
摘要: Recently Jonsson et al . reported on increased cortical bone mineralization as a side effect in imatinib treated adult patients with chronic myelogenous leukemia (CML).[1][1] Also for pediatric CML targeted therapy by this tyrosine kinase inhibitor has been replacing stem cell transplantation (SCT)
haematologica.org
sci-hub.se 参考文章(13)
S. Jonsson, B. Olsson, C. Ohlsson, M. Lorentzon, D. Mellstrom, H. Wadenvik, Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. ,vol. 93, pp. 1101- 1103 ,(2008) , 10.3324/HAEMATOL.12373
M Suttorp, Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplantation. ,vol. 42, ,(2008) , 10.1038/BMT.2008.282
Stephen Fitter, Andrea L. Dewar, Panagiota Kostakis, L. Bik To, Timothy P. Hughes, Marion M. Roberts, Kevin Lynch, Barrie Vernon-Roberts, Andrew C. W. Zannettino, Long-term imatinib therapy promotes bone formation in CML patients Blood. ,vol. 111, pp. 2538- 2547 ,(2008) , 10.1182/BLOOD-2007-07-104281
Stefania Mariani, Fiorina Giona, Sabrina Basciani, Marina Brama, Lucio Gnessi, Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty The Lancet. ,vol. 372, pp. 111- 112 ,(2008) , 10.1016/S0140-6736(08)61023-5
Inge M. van der Sluis, Wim C. Hop, Johannes P.T.M. van Leeuwen, Huib A.P. Pols, Sabine M.P.F. de Muinck Keizer-Schrama, A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults. Hormone Research in Paediatrics. ,vol. 57, pp. 170- 179 ,(2002) , 10.1159/000058378
Susannah O'Sullivan, Dorit Naot, Karen Callon, Fran Porteous, Anne Horne, Diana Wattie, Maureen Watson, Jill Cornish, Peter Browett, Andrew Grey, Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. Journal of Bone and Mineral Research. ,vol. 22, pp. 1679- 1689 ,(2007) , 10.1359/JBMR.070719
S Osorio, A García Noblejas, A Duran, JL Steegmann, Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response American Journal of Hematology. ,vol. 82, pp. 394- 395 ,(2007) , 10.1002/AJH.20778
Liju Yang, Vijaylaxmi Grey, Pediatric reference intervals for bone markers Clinical Biochemistry. ,vol. 39, pp. 561- 568 ,(2006) , 10.1016/J.CLINBIOCHEM.2005.11.015
F Millot, J Guilhot, B Nelken, T Leblanc, E S De Bont, A N Békassy, H Gadner, S Sufliarska, J Stary, H Gschaidmeier, F Guilhot, M Suttorp, Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation Leukemia. ,vol. 20, pp. 187- 192 ,(2006) , 10.1038/SJ.LEU.2404051
Ellin Berman, Maria Nicolaides, Robert G. Maki, Martin Fleisher, Suzanne Chanel, Kelly Scheu, Bri-Anne Wilson, Glenn Heller, Nicholas P. Sauter, Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate The New England Journal of Medicine. ,vol. 354, pp. 2006- 2013 ,(2006) , 10.1056/NEJMOA051140